Bionews Staff,  writers and editors—

Researchers at Kent and Canterbury Hospital, U.K., are recruiting 20 patients with multiple sclerosis (MS) who can walk at least eight meters with a walking aid to test the effectiveness of a five-week exercise program using assistive robotic technology. A patient completes balance and strengthening exercises using the…

Jeffrey Cohen, MD, director of the experimental therapeutics program at the Mellen Center for Multiple Sclerosis Treatment and Research at the Cleveland Clinic, is the newly named  president of ACTRIMS, the Americas Committee for Treatment and Research in Multiple Sclerosis. Cohen’s appointment concluded the 2019 ACTRIMS Forum that ran…

MS PATHS, a way of capturing data on disease progression and treatment response in thousands of multiple sclerosis (MS) patients being treated at any of 10 participating clinics, has among its goals that of making clinical remission — a prolonged absence of any disease activity — possible, said an…

Substantial data supporting both the effectiveness and safety of Mavenclad (cladribine tablets) is before the U.S. Food and Drug Administration (FDA), and may lead to its approval as a short-course oral treatment for people with relapsing-remitting multiple sclerosis (RRMS) some seven years after a first such request…

Mouse studies of siponimod — a potential progressive multiple sclerosis (MS) treatment that’s up for approval in the U.S. and EU — were among presentations given by Novartis at the 34th European Committee for Treatment and Research in Multiple Sclerosis (ECTRIMS), held Oct. 10-12 in Berlin. Animal work might seem…

A person’s genes influence the development of multiple sclerosis (MS), but so does the environment — both that in which an MS patient lives, and that which a patient creates through diet and other lifestyle choices, researchers said in a Thursday session at the 34th congress of the European…

Data from two European trials — a real-life study in Italy, and a long-term Czech trial looking at impact on cognition — supported the efficacy of a widely approved cannabinoid spray in treating moderate to severe spasticity (muscular stiffness or involuntary spasms) in multiple sclerosis (MS) patients who…

Thousands of scientists, doctors, pharmaceutical company executives and others — representing about 100 countries — will meet for three days to discuss and debate the latest developments in multiple sclerosis (MS) at the 34th Congress of the European Committee for Treatment and Research in Multiple Sclerosis, best known as…

A giant leap in research and interest in progressive multiple sclerosis — from a few people pushing for such work to 2,000 listening to updates on it — a successful first trial in children, and a growing body of potentially safer treatments for relapsing MS were among the highlights of…

Potential new ways of capturing disease progression in multiple sclerosis (MS) patients — including those with chronic as opposed to active inflammation — are coming to the fore as analyses continue into the huge amounts of data collected during pivotal clinical trials that led to Ocrevus’ approval, a leading Genentech researcher…

Lemtrada (alemtuzumab) remains a “game-changer” of a treatment for relapsing multiple sclerosis (MS), with benefits continuing and no new side effects seen in a study of its use that now goes out seven years, Aaron Boster, a neuroimmunologist at Ohio Health, said in an interview at the…

This is a special edition of Multiple Sclerosis News Today's daily Alexa Flash Briefing, covering the latest news from the 7th Joint ECTRIMS-ACTRIMS Meeting currently underway in Paris, France. The MS News today team in on-site at the conference, providing exclusive coverage of the presentations and speakers.

A bicycle specially designed to mimic the symptoms of multiple sclerosis (MS) now has its own owner’s manual, and the group behind the bike’s creation is inviting anyone interested to build their own experience of the spasticity and physical discomforts so well-known to people with the disease. The manual, which…

Dr. Fred Lublin, a neuroimmunologist with a specialty in experimental therapies, will open this year’s annual meeting of the Consortium of Multiple Sclerosis Centers on June 1 with an address questioning the continuing importance of relapses in multiple sclerosis (MS). But the question raised by the title of the…

When the 2016 annual meeting of the Consortium of Multiple Sclerosis Centers (CMSC) opens June 1, marking the organization’s 30th anniversary, at its head will be its executive director, June Halper. The honor is fitting. Halper, a nurse practitioner with a specialty in multiple sclerosis (MS) since 1978, has…

Genentech recently announced that the U.S. Food and Drug Administration (FDA) granted its investigational medicine ocrelizumab, a potential treatment for primary progressive multiple sclerosis (PPMS), Breakthrough Therapy Designation based on positive Phase 3 clinical trial results showing that ocrelizumab significantly reduced disability progression and other disease activity markers compared to placebo. The FDA designation is…

One of the teams participating in the 10th anniversary of the MS Melbourne Cycle, an annual biking challenge to raise money for MS Australia, has built a bicycle that as closely as possible replicates the physical difficulties and discomforts that typify multiple sclerosis (MS). A collaboration between the company Grey Australia, paralympic athlete Carol…

An interactive event in Coral Gables, FL this weekend will give relapsing Multiple Sclerosis patients who live in the area access to best practices and therapeutic insights that can help them better manage the disease. The Coral Gables MS Exchange event will be held from 10:30 a.m. to 2:15 p.m. on…

https://multiplesclerosisnewstoday.com/wp-content/uploads/2015/10/ECTRIMS-Podcast-2-091015-8.32-pm.mp3   Read the articles mentioned in the podcast: #ECTRIMS2015 – Another Attendee Record #ECTRIMS2015 – “Vitamin D plays important role in MS inflammation.” – Jorge Correale #ECTRIMS2015 – “When you stop smoking you can decrease the risk of disease progression.” – Jorge Correale Discovering a New World in…

In an effort to access firsthand patient data as a means of improving healthcare and drug safety, the Food and Drug Administration (FDA) has announced a unique partnership with  PatientsLikeMe, an online network of 350,000 patients who have reported on their own personal experiences in living with over 2,500 different diseases. The…

Concert Pharmaceuticals, Inc. will announce their latest results from the Phase 1 data of CTP-354, a drug developed to treat spasticity — a chronic condition associated with patients with brain disorders, including Multiple Sclerosis — at the next American Neurological Association’s Annual Meeting in Baltimore, Maryland. The Phase 1 randomized,…

Researchers have recently discovered that the fatigue that patients with multiple sclerosis (MS) experience is not the same kind of fatigue that healthy people feel from time to time, nor is it caused by the same factors. The National Multiple Sclerosis Society reports that around 80% of people who suffer from…

Multiple sclerosis (MS) patients who are prescribed Tysabri have an increased risk to develop the rare, often fatal infection of the brain called progressive multifocal leukoencephalopathy (PML), according to a recent study. PML is caused by a common virus that infects blood cells and can be mobilized by popular RRMS drug Natalizumab,…

Questcor Pharmaceuticals, Inc. is a drug development company with a viable Multiple Sclerosis drug called H.P. Acthar® Gel, which is currently approved in the U.S. by the FDA for the treatment of acute exacerbations of multiple sclerosis in adults. However, in addition to developing and commercializing MS therapies, the…

The National Center of Neurology and Psychiatry, based in Japan, announced that they will initiate a 3-month clinical trial on 9 patients with multiple sclerosis, beginning in March. Multiple sclerosis is an autoimmune disease caused by mutations of lymphocyte immune cells, which attack and destroy a patient’s own nerve cells. Patients with multiple sclerosis typically…

Researchers from the Kessler Foundation have found that higher educational achievement reduces the negative impact of traumatic brain injury (TBI) on cognitive status. The study appeared in Archives of Physical Medicine & Rehabilitation. It was reported in the study that cognitive ability after experiencing TBI differs in individuals even when their injury levels were comparable. As…